Search
In a post-hoc analysis of 89bio's ENLIVEN phase 2b trial of pegozafermin presented at The Liver Meeting, data suggested that the therapy reduced progression to cirrhosis for MASH patients
CEO Rohan Palekar describes this result that was presented at the meeting, as well as other biomarker findings. Plus, he highlights three...
Nov 16, 2024
An overview of Chugai, including its global ambitions and R&D capabilities, with the company’s CEO, Dr. Osamu Okuda, in Tokyo
Dr. Okuda describes Chugai’s vision to be a Top Innovator in 2030, the science that the company excels in, including unique midsize...
Nov 14, 2024
Microbiotica is working on microbiome therapies in Cambridge, UK, with lead programs in immuno-oncology and inflammatory bowel disease
CEO Tim Sharpington describes the advances that have been made in the microbiome field over the last decade and introduces us to...
Nov 14, 2024
Cambridge, UK based Mestag Therapeutics last month announced a license and research collaboration with MSD to leverage the company's fibroblast platform to find inflammatory disease targets
CEO Susan Hill describes the role that fibroblasts play in regulating immune responses to inflammatory conditions and how Mestag is...
Nov 14, 2024
Tokyo based TMS has a lead program that aims to be the first new medicine for acute ischemic stroke in decades
CEO Takuro Wakabayashi describes the unmet need in stroke and how this asset found its way into to a partnership with RTW-based Corxel....
Nov 13, 2024
Tokyo based Heartseed is leveraging its expertise iPSCs and regenerative medicine to solve unmet needs in cardiovascular disease like heart failure
Founder and CEO Keiichi Fukuda describes the qualities that Heartseed has built into the cardiomyocytes it is developing to make them...
Nov 13, 2024
SITC 2024: Aulos Bioscience CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company's IL-2 redirecting antibody
He describes the safety and preliminary efficacy they have seen, including how patients are experiencing a lowering of Tregs. Plus, the...
Nov 9, 2024
SITC 2024: Marengo's CEO Zhen Su discusses the first-in-human data for the company's lead program, Invikafusp Alfa
He describes how this dual T-cell agonist is designed to cause the expansion and reprogramming of TIL's in the body. Plus, an update on...
Nov 9, 2024
SITC 2024: Compugen's CEO discusses ovarian cancer data for her company's TIGIT + PVRIG + pembro triplet combo
Anat Cohen-Dayag describes this SITC data, shares her opinion on the TIGIT field, and highlights an IL-18 program that is partnered with...
Nov 9, 2024
SITC 2024: Immatics CEO Harpreet Singh shares an update on clinical data presented at SITC for the company's Gen 1 and Gen 2 PRAME cell therapies
He describes the Gen 1 data in melanoma and more, and compares it to what we have seen with competitor TIL data. Also, why the Gen 2...
Nov 9, 2024
SITC 2024: With a TIL therapy having made it to the market for the first time this year, the CEO of KSQ Therapeutics describes what the next generation of TILs might look like
Qasim Rizvi says he believes TILs can have broad applicability in the solid tumor space. He describes how KSQ is knocking out SOCS1 and...
Nov 8, 2024
Texas Life Science Forum: Reglagene is aiming to get tubulin therapies across the blood brain barrier so they can treat brain cancers
CEO Richard Austin explains how the company hopes to acheive this with a small molecule therapy. Plus, why he moved the company from...
Nov 7, 2024
Texas Life Science Forum: 4M Therapeutics is aiming make therapies for the CNS that are safer and more tolerable than current treatments
CEO Pablo Lapeurta, previously CMO of Lexicon, describes the lead programs for biopolar disorder and Alzheimer's agitation. Plus, Houston...
Nov 7, 2024
Texas Life Science Forum: March Biosciences closed a $28.4M series A round last month to advance its CD5 targeting CAR-T
CEO Sarah Hein describes the rationale for CD5, and share her experience of what it was like making the raise come together. Brought to...
Nov 7, 2024
Texas Life Science Forum: Mongoose Bio is advancing a novel TCR-T program that was developed at MD Anderson and plans to take it into the clinic next year
CEO Neil Warma describes the unique approach to TCRs that could reduce toxicity and increase persistence compared to other programs....
Nov 7, 2024
Texas Life Science Forum: NKILT Therapeutics is emerging into the in-vivo proof of concept stage of testing its HLA-G targeting cell therapy
CEO Raphaël Ognar describes the progress his company has made over the last year and previews data it will be presenting at SITC and ASH....
Nov 7, 2024
BIO-Europe: Mendus is developing cancer immunotherapies that focus on dendritic cell biology - an AML program will have a data update at #ASH24
CEO Erik Manting describes the rationale for focusing on dendritic cell biology, and covers previous data the company has presented in...
Nov 5, 2024
BIO-Europe: Centauri Therapeutics is planning to use antibody recruiting sugars that are linked to a targeting agent to treat infectious disease and cancer
CEO Jennifer Schneider describes how these "Alphamers" are designed to work and discusses the company's upcoming plans to enter the...
Nov 5, 2024
BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aβ upstream of where most others have focused - the lead programs are in ophthalmology
Executive Chairman Alexander Gebauer describes this approach to aiming to prevent toxic amyloid beta clumps from developing in the first...
Nov 5, 2024
BIO-Europe: Norway's Calluna Pharma was created over the last year through the combo of two co's going after the inflammatory and fibrotic spaces. The lead asset will advance to two phase 2s next year
CEO Mark Gaffney describes the science behind the lead program, CAL101, which targets a Damage Associated Molecular Pattern protein...
Nov 5, 2024
.png){kind=logo}
